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We compared the clinical outcomes of adults with acute leukemia that received single-unit umbilical cord
blood transplantation (sUCBT) after conditioning with a busulfan/antithymocyte globulin (BU-ATG)ebased
regimen at University Hospital La Fe (n ¼ 102) or double-unit UCBT (dUCBT) after conditioning with a total
body irradiation (TBI)ebased regimen at the University of Minnesota (n ¼ 91). Nonrelapse mortality, relapse
and disease-free survival were similar in the 2 groups. Multivariate analyses, showed more rapid neutrophil
(hazard ratio [HR], .6; 95% conﬁdence interval [CI], .45 to .80; P ¼ .0006) and platelet recovery (HR, .59; 95% CI,
.43 to.83; P ¼ .002) after the BU-ATG-based conditioning and sUCBT. Although there was a lower risk of acute
graft-versus-host disease (GVHD) grade II to IV (HR, 2.81; 95% CI, 1.75 to 4.35; P < .001) after BU-ATG and
sUCBT, the incidences of grade III to IV acute and chronic GVHD were similar between the 2 groups. Regarding
disease-speciﬁc outcomes, disease-free survival in both acute myeloid leukemia and acute lymphoblastic
leukemia (ALL) patients were not signiﬁcantly different; however, a signiﬁcantly lower relapse rate was found
in patients with ALL treated with TBI and dUCBT (HR, .3; 95% CI, .12 to .84; P ¼ .02). In the context of these
speciﬁc treatment platforms, our study demonstrates that sUCB and dUCBT offer similar outcomes.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION regarding conditioning regimen, UCB unit selection, and
Umbilical cord blood (UCB) has become a frequently used
source of hematopoietic progenitor cells for allogeneic
transplantation in patients with acute leukemia [1-4]. Early
studies in adults reported low rates of engraftment, which
were mainly attributed to the low progenitor cell content of
UCB grafts [5-7]. For this reason, most centers have adopted
aminimum cell dose threshold of 2.5107 nucleated cells per
kilogram actual body weight. Unfortunately such a threshold
would exclude many adults from UCB transplantation (UCBT).
As a result, the double UCB transplantation (dUCBT) strategy
was established to overcome this limitation andmake UCB an
adequate source of hematopoietic stem cells for nearly all
adults [8], and many adults receive a dUCBT if an adequate
single unit is not available [9].
Recent improvements in treatment regimens andUCB unit
selection algorithms have led some centers to re-evaluate the
cell dose limit. In fact, previous reports have shown that high
rates of engraftment can be achieved with lower cell dose
contents using an optimized busulfan-antithymocyte globulin
(BU-ATG)ebased regimen conditioning regimen and cord
blood unit selection, making single-unit UCBT (sUCBT) widely
available [10]. If the cell dose limit could be reduced, the added
cost of the second unit might be avoided.
The aim of this study was to compare the clinical
outcomes of adults with acute leukemia undergoing UCBT at
2 institutions using different transplantation platformsdgments on page 1729.
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13.09.015graft-versus-host disease (GVHD) prophylaxis.
PATIENTS AND METHODS
Eligibility Criteria
All consecutive adult patients over 15 years of age with acute leukemia
undergoing ﬁrst stem cell transplantationwith UCB from an unrelated donor
using myeloablative conditioning regimen between January 2001 and
December 2009 were eligible. All patients at University Hospital La Fe
(Valencia) underwent transplantationwith a single unit. Although about 25%
of adults at the University of Minnesota (Minneapolis) receive a single unit
containing >2.5  107 nucleated cells/kg, only recipients of a dUCBT were
included in the study. The upper age limit formyeloablative UCBTwas 45 and
55 years in Minneapolis and Valencia, respectively. Each center’s institu-
tional review boards approved treatment protocols and informed consent
was obtained according to the principles of the Declaration of Helsinki.
The treatment plans, including of unit selection, conditioning regimen,
immune suppression, and supportive care, have been reported by University
Hospital La Fe [1-4,11] and University of Minnesota groups [5-8,12] and are
summarized below.
Umbilical Cord Blood Unit Selection
Graft selection algorithm required that UCB units to be 4/6 HLA
matched with the recipient (HLA class I antigens [A and B] considering the
antigen level and class II antigen [DRB1] considering allele level resolution
DNA typing).
University Hospital La Fe
A total nucleated cell dose (TNC) 1.5  107/kg recipient’s body weight
was required until 2005. From 2006, TNC 2  107/kg and CD34þ cell dose
1  105/kg recipient’s body weight were required. Cell dose was consid-
ered the most important criteria for unit selection. All patients for which
donor search was initiated had a suitable UCB unit available according to the
above-mentioned criteria.
University of Minnesota
All patients from the University of Minnesota included in this analysis
received dUCB grafts selected according to the institutional algorithm. TheTransplantation.
Table 1
Characteristics of Patients
Characteristic Valencia
Cohort
Minneapolis
Cohort
P
Value
Patients, n 102 91
Age, median (range), yr 30 (16 to 52) 28 (15 to 45) .13
Male sex, n (%) 65 (64) 49 (54) .21
Weight, median (range), kg 70 (37 to 112) 73 (43 to 149) .4
Diagnosis, n (%) .42
AML 49 (48) 50 (55)
ALL 53 (52) 41 (45)
Disease stage at
transplantation, n (%)
.0003
First complete remission 54 (53) 49 (54)
Second or beyond complete
remission
20 (20) 35 (38)
Relapsed or refractory 28 (27) 7 (8)
CMV seropositive recipient,
n (%)
79 (77) 49 (54) .0009
Time from diagnosis to
transplantation for
patients in CR1, median
(range), mo
182 (27 to 331) 127 (67 to 343) .4
CMV indicates cytomegalovirus; AML, acute myeloid leukemia; ALL, acute
lymphoblastic leukemia.
Percentages may not total 100 because of rounding.
Table 2
Graft and Transplantation-Related Characteristics
Characteristic Valencia
Platform
Minneapolis
Platform
P
Value
HLA compatibility, n (%)* .24
6 of 6 7 (7) 6 (7)
5 of 6 21 (21) 28 (31)
4 of 6 74 (73) 57 (63)
ABO blood group mismatch, n (%) <.0001
Major 24 (24) 43 (47)
Minor 34 (33) 35 (38)
None 44 (43) 13 (14)
Nucleated cells infused  107/kg,
median, n (range)
2.5 (1 to 5.8) 3.6 (2 to 6.3)y <.0001
Percentages may not sum to 100 because of rounding.
* For double umbilical cord transplantation, the unit with the highest HLA
disparity was considered.
y After adding the cell dose of 2 cord blood units infused
J. Sanz et al. / Biol Blood Marrow Transplant 19 (2013) 1725e17301726combined minimum TNC dose was 2.5 107/kg of recipient’s body weight
with 1 unit having a cell dose1.5107/kg. The 2 UCB units were infused in
random order within 30 minutes of each other.
Conditioning Regimen and GVHD Prophylaxis
University Hospital La Fe
All patients received thiotepa, busulfan, cyclophospamide or ﬂudar-
abine, and ATG [4-8]. Until March 2005, 30 patients received thiotepa
(10 mg/kg), busulfan (9.6 mg/kg i.v.), cyclophosphamide (120 mg/kg) and
ATG (Thymoglobulin, Genzyme Transplant, Cambridge, MA; 8 mg/kg). From
March 2005, the remaining 72 patients received the same preparative
regimen but replacing cyclophosphamide by ﬂudarabine (150 mg/m2).
For GVHD prophylaxis, all patients received cyclosporine combined with
either long course prednisone in the ﬁrst 62 patients (.5mg/kg/day on daysþ7
to þ14, 1 mg/kg/day on days þ14 to þ28, with slow tapering until discon-
tinuation on day þ180), mycophenlate mofetil (MMF) (15 mg/kg/12 hours
until day þ28) in the following 35 patients, or a short course of prednisone in
the last 5 patients (1 mg/kg/day on days þ14 to þ28).
University of Minnesota
All patients received myeloablative conditioning consisting of cyclo-
phosphamide 120 mg/kg i.v. divided in 2 daily doses, ﬂudarabine 75 mg/m2
i.v. divided in 3 daily doses, and total body irradiation (1320 cGy) delivered
in 8 fractions over 4 days. The GVHD prophylaxis with cyclosporine A,
starting intravenously on day -3 with a target trough level of 200 mg/L to 400
mg/L, that, in case of no GVHD, was tapered over 10 weeks starting at
day þ100. Patients also received MMF starting i.v. at day 3, before 2006 at
a dose of 2 g/day and, from 2006, 3 g/day, that was discontinued at day þ30
in case of no acute GVHD [8,9].
Deﬁnitions
Myeloid recovery was deﬁned as the ﬁrst day of an absolute neutrophil
count of 0.5  109/L lasting for 3 or more consecutive days. Platelet recovery
was deﬁned as the ﬁrst day of a platelet count of 20  109/L or higher,
without transfusion support for 7 consecutive days. Patients who survived
more than 28 days after transplantation and who failed to achieve myeloid
engraftment were considered as primary graft failure. Acute and chronic
GVHD were deﬁned and graded according to standard criteria [10,13-15].
Disease stage at the time of transplantation was classiﬁed as follows: (1)
early stage: ﬁrst complete remission (CR1); (2) intermediate stage: second
or further CR; and (3) advanced stage: not in remission. Donor and recipient
HLA match for dUCBT was considered taking into account the cord blood
unit with the highest HLA disparity. Nonrelapse mortality (NRM) was
deﬁned as death from any cause without evidence of relapse. Leukemia-free
survival (LFS) was deﬁned as survival from the time of transplantation
without evidence of leukemia relapse.
Statistical Analysis
Patient and transplantation characteristics from different series were
compared using the chi-square test for categorical variables and the Wil-
coxon rank-sum test for continuous variables. The probabilities of engraft-
ment, NRM, GVHD, and relapse were estimated by the cumulative incidence
method (marginal probability) [16-17]. For cumulative incidence analyses of
engraftment, GVHD, and relapse, death in CR was considered as a competing
cause of failure, whereas relapse was the competing event for NRM. Unad-
justed time-to-event analyses were performed using the Kaplan-Meier
estimate [18], and, for comparisons, the log-rank tests [19]. Disease-free
survival was calculated from the date of UCBT. In the analysis of LFS,
relapse, or death in CR, whichever occurred ﬁrst was considered an
uncensored event. The follow-up of the patients was updated on October 1,
2012. A Cox proportional hazards model [20] or the Fine and Gray method
for competing events [21] were used for multivariable analysis. Variables
included in themodels were treatment platform, age, gender, recipient body
weight, transplantation period, recipient cytomegalovirus serostatus,
diagnosis (acute myeloid leukemia [AML] versus acute lymphoblastic
leukemia [ALL]), disease stage at transplantation, and HLA compatibility.
Statistical analysis were conducted using R version 2.12.2 (The CRAN
project) with packages, survival v2.36-10, Design 2.3-0, prodlim v1.2.1 and
cmprsk v2.2-2 [22].
RESULTS
Patient, Umbilical Cord Blood Unit, and Transplantation
Characteristics
Table 1 summarizes the demographic characteristics of
the 102 and 91 patients at the University Hospital La Fe and
the University of Minnesota, respectively. Patient and diseasecharacteristics were similar in both groups, except for
a higher proportion of patients that were CMV seropositive
(77% versus 54%; P ¼ .0009), and with relapsed or refractory
disease at time of transplantation (27% versus 8%; P¼ .003) in
the Valencia group. The median follow-up for surviving
patients was 76 months (range, 39 to 130) and 61 months
(range, 23 to 121), respectively. The median date of trans-
plantation was December 2006 in the Valencia cohort and
June 2006 in the Minneapolis group. Table 2 summarizes the
characteristics of the cord blood units.
Hematopoietic Engraftment
Myeloid engraftment
In the Valencia cohort, 2 patients died on days 12 and
19 after UCB infusion without evidence of myeloid engraft-
ment, 3 patients experienced primary graft failure, 2 patients
with initial neutrophil recovery subsequently lost the graft,
and the remaining 95 patients achieved stable myeloid
engraftment at a median time of 20 days (range, 12 to 57). In
the Minneapolis cohort, 12 patients experienced primary
graft failure, 1 patient with initial neutrophil recovery
Figure 1. Cumulative incidence of neutrophil recovery after UCB trans-
plantation with either Valencia or Minneapolis platforms.
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achieved stable myeloid recovery at amedian time of 24 days
(range, 14 to 52). The cumulative incidence of sustained
myeloid recovery at 60 days in the Valencia and Minneapolis
cohorts was 93% and 86%, respectively (P ¼ .002) (Figure 1).
In multivariable analysis, the Valencia platform was associ-
ated with a better neutrophil recovery (P ¼ .0006) (Table 3).
Time to neutrophil recovery and engraftment correlated
with CD34þ cell dose in the Valencia (HR,1.19; 95% CI, 1.06 to
1.34; P ¼ .003) and in the Minneapolis (HR, 1.15; 95% CI, 1.07
to 1.24; P ¼ .0003) cohorts.
Platelet engraftment
Of the 95 patients with myeloid engraftment in the
Valencia cohort, 16 patients died between 22 and 250 days
after transplantation without platelet recovery. The remain-
ing 79 patients had platelet engraftment at a median time of
53 days (range, 23 to 142). Of the 78 patients with myeloid
engraftment in the Minneapolis cohort, 17 patients died
between 44 and 143 days after transplantation without
platelet recovery. The remaining 61 patients had platelet
engraftment at a median time of 97 days (range, 35 to 450).
The cumulative incidence of sustained platelet engraftment
at 100 days in the Valencia and Minneapolis cohorts was 77%
and 62%, respectively (P¼ .001). In multivariable analysis, the
Valencia platform was associated with a better platelet
recovery (P ¼ .002) (Table 3).Table 3
Multivariable Analysis of Short and Long-Term Outcomes for All Patients
according to UCBT Platform
Outcome Relative Risk (95% CI) P
Value
Valencia
Platform
Minneapolis
Platform
Myeloid engraftment 1 .6 (.44 to .802) .0006
Platelet engraftment 1 .59 (.43 to .83) .002
Acute GVHD, grade II to IV 1 2.81 (1.75 to 4.35) <.0001
Chronic GVHD 1 .7 (.31 to 1.60) .4
Transplantation-related
mortality
1 1.06 (.66 to 1.71) .8
Relapse 1 .52 (.25 to 1.08) .08
Leukemia-free survival 1 1.27 (.86 to 1.88) .23
GVHD indicates graft-versus-host disease.GVHD
Acute GVHD
In the Valencia cohort, 51 of the 95 evaluable patients
with stable engraftment developed acute GVHD (aGVHD).
Acute GVHD grade I was observed in 25 patients, grade II in
10 patients, grade III in 12 patients, and grade IV in 4
patients. The median time to the development of acute
GVHD grade II to IV was 16 days (range, 8 to 91). In the
Minneapolis cohort, 59 of the 78 evaluable patients with
stable engraftment developed aGVHD. Acute GVHD grade I
was observed in 5 patients, grade II in 34 patients, grade III
in 16 patients, and grade IV in 4 patients. The median time to
the development of acute GVHD grade II to IV was 23 days
(range, 13 to 69).
The cumulative incidence of aGVHD at 100 days in the
Valencia andMinneapolis cohorts was 28% and 69% for grade
II to IV, respectively (P < .0001), whereas for grade III to IV it
was 17% and 26%, respectively (P ¼ .2). In multivariable
analysis, the Minneapolis platform was associated with an
increased risk of aGVHD grades II to IV (P < .0001) (Table 3).
No factor was associated with the risk of grade III to IV
aGVHD.
Chronic GVHD
Thirty-nine of 78 patients at risk in the Valencia cohort
developed chronic GVHD (cGVHD) at a median time of 140
days (range, 70 to 415). Chronic GVHD was limited in
16 patients and extensive in 23 patients. In the Minneapolis
cohort, 24 of 67 patients at risk developed cGVHD at
a median time of 153 days (range, 92 to 558). Chronic GVHD
was limited in 5 patients and extensive in the remaining
19 patients.
The 2-year cumulative incidence of any cGVHD and
extensive cGVHD in the Valencia and Minneapolis cohorts
was 50% and 36% (P ¼ .06) and 29% and 28% (P ¼ .8),
respectively. No factor was associated with the risk of cGVHD
in multivariable analysis.
NRM
Thirty-six patients in the Valencia cohort died without
prior relapse at a median time of 125 days after trans-
plantation (range, 12 to 2535), whereas in the Minneapolis
cohort, 32 patients died at a median time of 62 days after
transplantation (range, 24 to 765). The cumulative incidence
of NRMwas similar in both groups (P¼ .8). For patients in the
Valencia cohort, the incidence of NRM at 100 days, 180 days,
and 5 years was 13%, 20%, and 34%, respectively. For patients
in the Minneapolis cohort, the incidence of NRM at 100 days,
180 days, and 5 years was 24%, 30%, and 35%, respectively. No
factor was associated with the risk of NRM in multivariable
analysis.
Relapse
Overall, 32 patients in the Valencia cohort relapsed at
a median time of 4.5 months (range, 1 to 50) and 12 patients
in the Minneapolis cohort relapsed at a median time of 6.8
months (range,1 to 22). All relapsed patients died at amedian
time of 64 days (range, 2 to 1129). Relapse incidence was
different depending on diagnosis, with a 5-year cumulative
incidence of relapse of 40% and 24% for patients with ALL and
AML, respectively (P ¼ .04). The 5-year cumulative incidence
of relapse was 42% for the Valencia cohort and 19% for the
Minneapolis cohort (P ¼ .004). The 5-year cumulative inci-
dence of relapse was 70% versus 66% (P ¼ .9) for patients in
advanced stage and 31% versus 14% (P¼ .04) for patients in CR
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However, in multivariable analysis, only advanced disease
status at time of transplantation was associated with
increased risk of relapse (P < .0001).
When the analysis was restricted to patients with AML,
the 5-year cumulative incidence of relapse was 23% and 13%
for the Valencia and Minneapolis cohorts, respectively
(P ¼ .3). In multivariable analysis, advanced disease status
at time of transplantation (P < .0001) and better HLA match
(6/6 versus 5/6 versus 4/6) (P < .001) were the only inde-
pendent factors independently associated with an increased
risk of relapse (Table 4).
In patients with ALL, the 5-year cumulative incidence of
relapse was 40% and 12% for the Valencia and Minneapolis
cohorts, respectively (P ¼ .003). In multivariable analysis,
advanced disease status at time of transplantation (P¼ .0006)
and the Valencia platform (P ¼ .02) were associated with an
increased risk of relapse (Table 4).LFS
Thirty-four patients in the Valencia cohort and 47
patients in the Minneapolis cohort were alive and leukemia
free after UCB transplantation at last follow-up. The overall
LFS at 5 years was 34% and 52% for the Valencia and Min-
neapolis cohorts, respectively (P ¼ .05). The 5-year LFS was
21% versus 29% (P ¼ .9) for patients in advanced stage, and
40% versus 53% (P¼ .2) for patients in CR for the Valencia and
Minneapolis cohorts, respectively. The 5-year LFS was 49%
for patients with AML and 35% for patients with ALL (P¼ .04).
In multivariable analysis, advanced disease status at time of
transplantation was the only factor associated with higher
risk of treatment failure (P < .0001).
The 5-year LFS for patients with AMLwas 45% for patients
in the Valencia cohort and 54% in the Minneapolis cohort
(P ¼ .4) and 50% versus 55% (P ¼ .7) for patients in CR,
respectively (Figure 2). No factor was signiﬁcantly associated
with LFS in patients with AML in multivariable analysis. In
patients with ALL, the 5-year LFS was 24% for patients in the
Valencia cohort and 49% for those in the Minneapolis cohort
(P ¼ .08), and 30% versus 51% (P ¼ .2) for patients in CR,
respectively (Figure 3). In multivariable analysis, advanced
disease status at time of transplantation was the only factorTable 4
Multivariable Analysis of Disease-Speciﬁc Outcomes: Relapse Risk and Leukemia-F
Outcome Variable Acute Myeloid L
Relative risk (95
Relapse
UCBT platform
Valencia 1
Minneapolis .6 (.24 to 1.57
Disease status
Complete remission 1
Relapse/refractory 10.1 (3.50 to 29
HLA match
6/6 1
5/6 .12 (.02 to .60)
4/6 .09 (.03 to .31)
Leukemia-free survival
UCBT platform
Valencia 1
Minneapolis 1.26 (.73 to 2.19
Disease status
Complete remission -
Relapse/refractory -
UCBT indicates umbilical cord blood transplantation.associated with higher risk of treatment failure (P ¼ .007)
(Table 4).DISCUSSION
This study shows the relative efﬁcacy of 2 UCBT platforms
in adults with acute leukemia, which were carried out at
2 institutions using either a BU-ATGebased conditioning
with sUCBT (Valencia platform) and TBI-based conditioning
with dUCBT (Minneapolis platform). Themain observation of
this study is that sUCBT can be a suitable graft source.
Although numerous reports have previously established the
minimum cell dose threshold of 2.5  107 nucleated cells/kg,
it is possible that this needs to be reconsidered, especially in
the context of speciﬁc conditioning regimens. Whether the
same results would have been observed with a sUCB unit
after cyclophosphamide, ﬂudarabine, and TBI as used in
Minneapolis is not known. This might be addressed in future
studies.
In the present study, we have had the opportunity to
compare the outcome of 2 relatively large single-center
series of adult patients with acute leukemia undergoing
UCBT in 2 institutions experienced in UCBT. High rates of
myeloid and platelet engraftment were achieved in the
Valencia cohort and compare favorably with theMinneapolis
cohort and with those reported in registry-based studies
[23,24]. The addition of thiotepa to a BU-ATGebased condi-
tioning regimen, as used in the Valencia cohort, appears to
permit the routine use of lower dosed single units. Further-
more, it is possible that MMF may delay or reduce engraft-
ment in some patients, as myelosuppression is a known
complication and has been previously reported [25-27]. Why
a faster engraftment and a lower graft failure rate in the
Valencia cohort did not translate into a lower NRM remains
unexplained and is probably multifactorial.
As previously described [28], grade II acute GVHD with
involvement principally of the skin was more frequently
observed in recipients of dUCBT as compared with recipients
of UCBT, without a clear impact on NRM. The reason for the
relatively low GVHD rate in the Valencia cohort is unproven,
but we speculate that the use of rabbit ATG in the condi-
tioning regimen may have contributed to this observation.
Although it is possible that a lower CD3 cell dose inherent inree Survival
eukemia Acute Lymphoblastic Leukemia
% CI) P Value Relative Risk (95% CI) P Value
.3 .02
1
) .3 (.12 to .84)
<.0001 .0006
1
.1) 4.32 (1.86 to 9.74)
.01 -
<.0001 -
.4 .15
1
) 1.48 (.87 to 2.54)
.007
1
.44 (.24 to .80)
Figure 2. Probability of leukemia-free survival in patients with acute myeloid
leukemia in remission after UCB transplantation with either Valencia or
Minneapolis platforms.
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have not observed an association between CD3 cell dose and
acute GVHD. Incidences of acute grade III to IV and chronic
GVHD were comparable in both cohorts. Although the
addition of ATG could have hampered immune reconstitu-
tion in the Valencia cohort, a detailed analysis is unavailable.
However, there was no signiﬁcant difference in NRM in the
present study and the incidence of cytomegalovirus reac-
tivation previously reported from both groups was also
similar [29,30].
Regarding relapse, it has been suggested a lower rate of
relapse for patients receiving dUCBT indicates a potentially
higher graft-versus-leukemia (GVL) effect [12,31,32].
However, this is, to date, an unexplained ﬁnding that has not
been uniformly conﬁrmed [33]. In the present study, the only
variable with independent prognostic value for relapse was
disease stage at time of transplantation, and after adjusting
for this variable and various known risk factors, relapse was
not associated with the cohort. Interestingly, relapse risk
may be more associated with degree of HLAmismatch ratherFigure 3. Probability of leukemia-free survival in patients with acute
lymphoblastic leukemia in remission after UCB transplantation with either
Valencia or Minneapolis platforms.than the use of a dUCBT, as has been previously suggested by
other studies [12]. In fact, for both groups, we observed an
impressive reduction in the risk of relapse in patients with
AML, suggesting an enhanced GVL effect for patients who
underwent transplantationwith UCB units with a higher HLA
disparity. In this regard, previous registry-based studies from
Eurocord [34] and the Japanese Society for Hematopoietic
Cell Transplantation group [35] have also found that UCBTs
with a higher HLA disparity had a lower probability of
relapse. In contrast to pediatric patients, this effect does not
seem to be counterbalanced with an increased NRM as
suggested by large registry-based studies [35-37]. Although
there was a lower risk of relapse in the Minneapolis patients
with ALL, it is unclear whether this was due to the condi-
tioning that included TBI, the use of 2 units, or the absence of
in vivo T cell depletion with ATG.
In conclusion, this retrospective study demonstrated that
in the context of the speciﬁc treatment platforms employed
in Valencia and Minneapolis, sUCB and dUCBT offer similar
outcomes. Future studies are needed to determine whether
this ﬁnding is true for all or only speciﬁc scenarios. In addi-
tion, the ﬁnding that HLA mismatch does not compromise
LFS and may indeed enhance the GVL effect also needs
further investigation. Together, these 2 ﬁndings could have
a signiﬁcant impact on the practice of transplant medicine.
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